PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma
Metrics: PDF 1341 views | HTML 2482 views | ?
Anna Cordeiro1, Alfons Navarro1, Anna Gaya2, Marina Díaz-Beyá2, Blanca Gonzalez-Farré3, Joan Josep Castellano1, Dolors Fuster1, Carmen Martínez2, Antonio Martínez3, Mariano Monzó1
1Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
2Hematology Department, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain
3Hematopathology Section, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain
Alfons Navarro, email: email@example.com
Keywords: Hodgkin lymphoma, non-coding RNAs, piwiRNAs, piR-651, Piwi proteins
Received: March 04, 2016 Accepted: May 26, 2016 Published: June 14, 2016
PiwiRNAs, small non-coding RNAs processed by Piwi proteins, are involved in maintaining genome stability in germline cells. Recently, piwiRNA expression has been identified in some tumors. We have examined the potential reactivation of the Piwi/piwiRNA pathway in classical Hodgkin lymphoma (cHL). We found that Piwi proteins and three selected piwiRNAs, including piR-651, were expressed in cHL patients and cell lines, indicating that the Piwi/piwiRNA pathway is active in cHL. Interestingly, low levels of piR-651 were associated with lack of complete response to first-line treatment, as well as shorter disease-free and overall survival in a cohort of 94 cHL patients. At diagnosis, piR-651 was underexpressed in cHL serum samples compared to healthy controls, while after complete remission, piR-651 levels increased to levels similar to healthy controls. This is the first evidence that piwiRNAs are active in tumor and serum samples and impact prognosis in cHL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.